41 Using advanced statistical modeling, we found that home AED use was associated with improved outcomes among patients presenting with an initial shockable rhythm, representing approximately 16% of all patients. Survival to hospital discharge increased from 22% to 28%, representing a 26% relative increase, and this finding was both robust and statistically significant. In contrast, home AED use did not improve outcomes among patients with a non-shockable rhythm, for whom survival was approximately 4.5% regardless of AED use. This finding is consistent with the mechanism of an AED, which delivers a shock only when a shockable rhythm is detected. In our cost-effectiveness analysis, we considered both the clinical benefits of home AED use and the associated costs, primarily the cost of purchasing the device. Because cardiac arrest in any specific home is rare and difficult to predict, AEDs would need to be placed in a very large number of homes to ensure availability when needed. This reality was reflected in our results. To gain one quality-adjusted life year (QALY)—defined as one additional year of life in perfect health—the estimated cost was approximately $4.5 million USD. This value is substantially higher than commonly accepted cost-effectiveness thresholds, indicating that indiscriminate purchase of AEDs for all private homes is not currently cost- effective. However, this conclusion may change under certain circumstances. If future studies can identify individuals or households at particularly high risk of cardiac arrest, targeted AED placement in those homes could potentially become cost- effective. Alternatively, the cost of AED devices may decrease over time, which could also improve cost-effectiveness in the home setting. Our study highlights the unique value of the CARES registry for addressing important clinical and public health questions related to cardiac arrest. In summary, AED use in private homes improves survival among patients presenting with a shockable rhythm. Because cardiac arrests at home are common at the population level, expanding access to AEDs in residential settings has the potential to save thousands of lives each year. However, given the low event rate within individual homes and the current cost of devices, our analysis suggests that routine purchase of AEDs for all private residences cannot currently be considered cost-effective. 1. Andersen, L. W., Holmberg, M. J., Krijkamp, E., Stankovic, N., Meilandt, C., Vallentin, M. F., Høybye, M., Folke, F., Kunst, N., Dijk, S., Granfeldt, A., & Caulley, L. (2026). Effectiveness and cost-effectiveness of automated external defibrillators in private homes: A report from the Cardiac Arrest Registry to Enhance Survival. JAMA Internal Medicine, 186(1), 37–43. https://doi.org/10.1001/jamainternmed.2025.6123 Figure 1. Relationship between cardiac arrest incidence and the incremental cost-effectiveness ratio. The x-axis represents the yearly incidence of cardiac arrest for each household member. The base case incidence was 0.06% (vertical dotted line). At a yearly incidence above 0.6%, having an AED in a private home would be considered cost-effective at a willingness-to-pay threshold of $200,000 (horizontal dotted line). From Andersen LW, Holmberg MJ, Krijkamp E, et al. Effectiveness and Cost-Effectiveness of Automated External Defibrillators in Private Homes: A Report From the Cardiac Arrest Registry to Enhance Survival. JAMA Internal Medicine. Published online October 25, 2025. doi:10.1001/ jamainternmed.2025.6123. Used with Permission. Copyright © 2025 American Medical Association. All rights reserved. Figure 1
View this content as a flipbook by clicking here.